Skip to content

Bioequivalence of a diabetes specific tube feed with a new carbohydrate source

Bioequivalence of a diabetes specific tube feed with a new carbohydrate source - EquiDia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51846
Enrollment
22
Registered
2022-07-26
Start date
2022-07-26
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

studie met gezonde vrijwilligers niet van toepassing

Interventions

Test product: diabetes specific tube feed new recipe (approximately 250 ml) Control product: diabetes specific tube feed original recipe (approximately 250 ml) Reference product: glucose solution (25
to determine the glycemic index of the test product

Sponsors

Nutricia Research
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 and = 18.5 and

Exclusion criteria

Exclusion criteria: 1. Known Diabetes Mellitus type I or type II, rebound hypoglycaemia and/or any other medical condition that 2. Any use of anticoagulants, systemic steroids, protease inhibitors or antipsychotics and/or any medication known to affect glucose tolerance and/or to influence digestion and absorption of nutrients within 1 week of screening, in opinion of the Investigator 3. Any known disease which influences digestion and absorption of nutrients within 1 week of screening (in the opinion of the Investigator) 4. Allergy to soy and/or any other known relevant food allergy or intolerance in opinion of the Investigator 5. Adherence to a strict vegan diet 6. Adherence to a weight loss program 7. Picky/fussy eater (being very selective about what to eat) or eating disorder 8. Known pregnancy and/or lactation 9. Current smoking or stopped smoking for 21 glasses per week for men or > 14 glasses per week for women (on average during the last 6 months) 11. Drug or medicine abuse in opinion of the Investigator 12. Any known bleeding disorder 13. Active participation in any other clinical study with investigational or marketed products concomitantly or within 4 weeks before study visit 1, in the opinion of the Investigator 14. Major medical or surgical event requiring hospitalization within the preceding 3 months and/or scheduled in the period of study participation relevant in the opinion of the Investigator 15. Investigator*s uncertainty about the willingness or ability of the subject to comply with the protocol requirements 16. Employees of Nutricia Research and/or family members or relatives of employees

Design outcomes

Primary

MeasureTime frame
Blood glucose iAUC0-120 [mmol/L*min] and the blood glucose iCmax [mmol/L] (test product versus control product)

Secondary

MeasureTime frame
- GI = blood glucose iAUC0-120 [mmol/L] of test product / mean blood glucose iAUC0-120 [mmol/L] of reference product - Glycemic Load (GL) = GI * available carbohydrate/given amount of carbohydrate

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)